Primary outcome
What DUALIV measured first
| IDegLiran=289 | Placebon=146 |
|---|---|
| -1.45(0.84) | -0.46(0.83) |
Phase 3 · Liraglutide
DUALIV trial results
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Change in Glycosylated Haemoglobin (HbA1c) (percentage of glycosylated haemoglobin), Week 0, Week 26. IDegLira: -1.45; Placebo: -0.46.
- Participants
- 435
- Status
- completed
- Completed
- 2013-10-23
- Sponsor
- Novo Nordisk A/S
As posted on ClinicalTrials.gov (NCT01618162), updated at source Oct 27, 2017. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Side effects by arm
Side effects in DUALIV
Percent of participants affected, After 26 weeks of treatment. The most common events the registry lists.
| Event | IDegLira | Placebo |
|---|---|---|
| Any serious event | 4.9% | 3.4% |
| Lipase increased | 9.4% | 4.1% |
| Nasopharyngitis | 8.7% | 8.2% |
| Dyslipidaemia | 6.6% | 4.1% |
| Headache | 5.2% | 5.5% |
| Influenza | 2.8% | 5.5% |
Secondary outcomes
What else it measured
| IDegLiran=289 | Placebon=146 |
|---|---|
| 79.2 | 28.8 |
| IDegLiran=289 | Placebon=146 |
|---|---|
| 64 | 12.3 |
| IDegLiran=286 | Placebon=144 |
|---|---|
| -2.6(2.61) | -0.31(2.43) |
| IDegLiran=289 | Placebon=146 |
|---|---|
| 0.5(3.1) | -1(2.6) |
| IDegLiran=288 | Placebon=146 |
|---|---|
| 351.7 | 135.2 |
| IDegLiran=288 | Placebon=146 |
|---|---|
| 401.4 | 367 |
The trial
How DUALIV was run
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled with SU (sulphonylurea) alone or in combination with metformin. All subjects will continue their pre-trial SU treatment with or without metformin treatment without changing the frequency or dose throughout the trial.
- Insulin degludec/liraglutide
- Placebo
Who could join the trial
Inclusion Criteria: * Subjects with type 2 diabetes mellitus * HbA1c 7.0-9.0% (53-75 mmol/mol) (both inclusive) * Subjects on stable daily dose of sulphonylurea (above or equal to half of the max approved dose according to local label) with or without metformin (above or equal to 1500 mg or max tolerated dose) for at least 90 days prior to screening visit (Visit 1) * Body Mass Index (BMI) below or equal to 40 kg/m\^2 Exclusion Criteria: * Any use of oral anti-diabetic drugs (OADs) (other than SU in monotherapy or in combinationwith metformin) below or equal to 90 days prior to screening visit (Visit 1) * Use of any drug (other than SU in monotherapy or in combination with metformin), which in the Investigators opinion could interfere with the blood glucose level (e.g. systemic corticosteroids) * Previous treatment with glucagon-like peptide-1 (GLP-1) receptor agonist (e.g. exenatide, liraglutide) * Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator) * Screening calcitonin above or equal to 50 ng/l * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) * Cardiovascular disorders defined as: congestive heart failure (New York Heart Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to screening visit (Visit 1) and/or planned coronary,carotid or peripheral artery revascularisation procedures * Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema) according to the Investigator's opinion * Subjects with a clinical significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the Type 2 Diabetes Mellitus),neurological, genitourinary or haematological system that in the opinion of the Investigator,may confound the results of the trial or pose additional risk in administering trial product * History of chronic pancreatitis or idiopathic acute pancreatitis
Published papers
Papers from DUALIV
- Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 2017 Feb;34(2):189-196. doi: 10.1111/dme.13256. Epub 2016 Oct 7.
- Khunti K, Mohan V, Jain SM, Boesgaard TW, Begtrup K, Sethi B. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program. Diabetes Ther. 2017 Jun;8(3):673-682. doi: 10.1007/s13300-017-0252-9. Epub 2017 Mar 22.
- Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.